The new assessment, says the Institute for Clinical and Economic Review (ICER), is intended to incorporate data that have emerged since the organization reviewed rheumatoid arthritis (RA) treatments in 2017, including data related to biosimilar infliximab, Inflectra.
The Institute for Clinical and Economic Review (ICER), a nonprofit organization that produces reports analyzing evidence on the effectiveness and value of drugs, has released a draft scoping document for the assessment of treatments for rheumatoid arthritis (RA).
The new assessment, says ICER, is intended to incorporate data that have emerged since the organization reviewed RA treatments in 2017, including data related to biosimilar infliximab, Inflectra.
While ICER said it will not perform a detailed economic analysis of biosimilars available for the treatment of RA, it will present data on biosimilars. These data will be presented separately from those related to innovator products, given differences present in biosimilars’ clinical study designs and intents relative to those of originator products. ICER says that it will explore the potential health system budgetary impact of biosimilar infliximab over a 5-year time horizon using available information on the potential population eligible for treatment and results from a simulation model for treatment costs.
The organization also notes that it will include information on wasteful or low-value services that can be reduced or eliminated to create additional resources in healthcare budgets for higher-value or innovative services.
ICER’s 2017 review of RA therapies, which focused on 11 drugs (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, abatacept, rituximab, sarilumab, tocilizumab, baricitinib, and tofacitinib), found that all of these products substantially improve patients’ health outcomes versus conventional disease-modifying antirheumatic drugs (DMARDs). However, these agents’ costs translate into cost-effectiveness estimates that exceed commonly cited thresholds.
Assuming a willingness to pay threshold of $150,000 per quality of life-year (QALY) gained, etanercept given in combination with a conventional DMARD was found to be cost-effective as a first-line therapy. Other drugs, including abatacept (in combination with a DMARD) and tofacitinib were estimated to have higher costs and fewer QALYs gained.
The 2017 report also called for regulatory intervention to curb the rising prices of these agents, which ICER said are “moving further from reasonable alignment with the added benefits to patients.”
Stakeholders are encouraged to submit their comments on the scoping document and on low-value care practices to ICER by May 1, 2019.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.